Tarsus Pharmaceuticals, Inc.
TARS
$58.85
$2.243.96%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.70% | 29.19% | 14.97% | -24.87% | -65.00% |
| Total Depreciation and Amortization | 48.09% | 35.67% | 39.68% | 81.53% | 130.13% |
| Total Amortization of Deferred Charges | 29.27% | 21.29% | 25.19% | 29.26% | 23.77% |
| Total Other Non-Cash Items | 2.59% | 31.03% | 60.27% | 79.44% | 87.47% |
| Change in Net Operating Assets | -6,262.45% | 253.04% | 1,156.21% | 111.51% | -85.79% |
| Cash from Operations | 34.72% | 50.58% | 29.33% | -12.52% | -64.57% |
| Capital Expenditure | -22.48% | -48.43% | -4.33% | 8.23% | -17.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -85.86% | -557.15% | -239.07% | -423.64% | -12.33% |
| Cash from Investing | -84.56% | -587.02% | -241.67% | -442.68% | -12.43% |
| Total Debt Issued | -100.00% | 1,400.00% | 650.00% | 650.00% | 1,500.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -35.91% | -34.94% | -12.05% | 21.70% | 28,075.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.85% | -478.00% | -- | -- | -- |
| Cash from Financing | -48.47% | -22.01% | 18.81% | 54.94% | 4,779.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -210.17% | -112.02% | -183.22% | -188.25% | 153.63% |